Analyst firms · BofA Securities · EW

BofA Securities EW price target and rating history

Edwards Lifesciences Corporation (EW) · Health Care

BofA Securities rates Edwards Lifesciences Corporation (EW) Buy with a $75 price target, as of its latest action on Dec 16, 2024. It has published 4 rating actions on EW since March 2022, including 2 upgrades and 1 downgrade. Across 7 firms with a EW price target in the last 12 months, the median target is $110.

Current rating
Buy
Price target
$75
Median target, all firms
$110
Actions on EW
4

BofA Securities price target on EW

$130$103$752023202420252026
BofA Securities price target on EW, each point a stated target, March 2022 to July 2024.

Every BofA Securities rating on EW

How other firms rate EW

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Robert W. BairdOutperform$116Nov 5, 2026
Truist SecuritiesBuy$113Nov 4, 2026
BarclaysOverweight$110Oct 7, 2026
UBSBuy$110Jul 28, 2026
Leerink PartnersOutperform$101Jul 24, 2026
Wolfe ResearchOutperform$92Apr 1, 2026
TD CowenBuy$97Jan 9, 2026

Questions about BofA Securities and EW

What is BofA Securities's price target for EW?
BofA Securities's latest stated price target for Edwards Lifesciences Corporation (EW) is $75, from its action on Jul 25, 2024.
What is BofA Securities's rating on EW?
BofA Securities rates EW Buy, a bullish rating, as of Dec 16, 2024.
When did BofA Securities last change its view on EW?
On Dec 16, 2024, BofA Securities upgrades to Buy from Neutral.
How does BofA Securities's EW target compare with other analysts?
Across 7 firms with a EW price target in the last 12 months, the median target is $110.

More EW rating histories

All BofA Securities ratingsEW news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.